Wilmanns W, Sauer H, Schalhorn A
Langenbecks Arch Chir. 1982;358:393-8. doi: 10.1007/BF01271823.
The interdisciplinary approach in the combined modality treatment of non-metastasized osteogenic sarcoma follows now well-established guidelines: (1) diagnostic biopsy; (2) pretherapeutic cytostatic polychemotherapy (cyclic administration of adriamycin, high-dose methotrexate or cis-platinum, BCD = bleomycin + cyclophosphamide + dactinomycin); (3) limb-saving oncological radical operation with histological evaluation of the effectiveness of the preoperative chemotherapy; (4) continuation of the preoperative chemotherapy as postoperative adjuvant chemotherapy. This interdisciplinary approach in the treatment of localized osteogenic sarcoma has improved the 5-year survival rate from 20% to 80%.
（1）诊断性活检；（2）术前细胞抑制性多药化疗（阿霉素、大剂量甲氨蝶呤或顺铂的周期性给药，BCD = 博来霉素 + 环磷酰胺 + 放线菌素D）；（3）保肢肿瘤根治手术，并对术前化疗效果进行组织学评估；（4）将术前化疗作为术后辅助化疗继续进行。这种治疗局限性骨肉瘤的多学科方法已将5年生存率从20%提高到了80%。
